Eiger BioPharmaceuticals, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $15.8M | $13.5M | $12.1M | $0 | — | — |
| Operating income | −$71.8M | −$92.7M | −$76.9M | −$62.1M | −$68.9M | −$51.0M |
| Net income | −$75.0M | −$96.8M | −$33.9M | −$65.1M | −$70.3M | −$52.4M |
| Total assets | $38.8M | $120.1M | $126.4M | $143.6M | $105.1M | $102.4M |
| Total liabilities | $53.3M | $64.8M | $54.0M | $48.6M | $48.7M | $35.9M |
| Equity | −$14.5M | $55.3M | $72.4M | $95.0M | $56.5M | $66.6M |
| EPS (diluted) | $-50.78 | $-69.74 | $-1.00 | $-2.31 | — | — |
| Shares out. | 44.2M | 34.6M | 33.9M | 24.6M | 19.3M | 10.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −455.1%
- Net margin
- −475.3%
- Return on equity
- 518.5%
- Return on assets
- −193.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 137.2%
- Debt / equity
- —
- Book value / share
- $-0.33
- Revenue growth (YoY)
- 17.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -58.32distress
- Accruals / assets
- −1.1%clean
- Beneish M-Score
- -3.25normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Modified shareholder rights · Other material eventOct 1, 2024
- Bankruptcy or receivership · Modified shareholder rightsSep 9, 2024
- Completed an acquisition or dispositionSep 4, 2024
- Regulation FD disclosureSep 3, 2024
- Entered a material agreementAug 2, 2024
- Regulation FD disclosureAug 1, 2024
- Regulation FD disclosureJul 16, 2024
- Completed an acquisition or dispositionJul 10, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.